41.61
-0.07 (-0.17%)
| Penutupan Terdahulu | 41.68 |
| Buka | 42.03 |
| Jumlah Dagangan | 1,462,963 |
| Purata Dagangan (3B) | 2,373,240 |
| Modal Pasaran | 5,154,979,840 |
| Harga / Jualan (P/S) | 7.81 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -59.05% |
| Margin Operasi (TTM) | -62.79% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 30.20% |
| Nisbah Semasa (MRQ) | 4.68 |
| Aliran Tunai Operasi (OCF TTM) | -239.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -146.83 M |
| Pulangan Atas Aset (ROA TTM) | -16.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,584.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | Guardant Health, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.30 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.79% |
| % Dimiliki oleh Institusi | 98.66% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (UBS, 68.23%) | Beli |
| Median | 60.00 (44.20%) | |
| Rendah | 55.00 (Stephens & Co., 32.18%) | Beli |
| 55.00 (Mizuho, 32.18%) | Beli | |
| Purata | 60.22 (44.73%) | |
| Jumlah | 9 Beli | |
| Harga Purata @ Panggilan | 46.37 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 06 May 2025 | 60.00 (44.20%) | Beli | 41.93 |
| Scotiabank | 05 May 2025 | 57.00 (36.99%) | Beli | 44.05 |
| Barclays | 01 May 2025 | 60.00 (44.20%) | Beli | 48.87 |
| 10 Apr 2025 | 55.00 (32.18%) | Beli | 41.14 | |
| Canaccord Genuity | 01 May 2025 | 65.00 (56.21%) | Beli | 48.87 |
| Stifel | 01 May 2025 | 60.00 (44.20%) | Beli | 48.87 |
| TD Securities | 01 May 2025 | 60.00 (44.20%) | Beli | 48.87 |
| UBS | 01 May 2025 | 70.00 (68.23%) | Beli | 48.87 |
| Mizuho | 10 Apr 2025 | 55.00 (32.18%) | Beli | 41.14 |
| Stephens & Co. | 26 Mar 2025 | 55.00 (32.18%) | Beli | 45.84 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JOYCE MEGHAN V. | - | 42.10 | -100 | -4,210 |
| KALIA KUMUD | - | 45.79 | -4,000 | -183,160 |
| TALASAZ AMIRALI | - | 48.67 | -119,284 | -5,847,821 |
| Jumlah Keseluruhan Kuantiti Bersih | -123,384 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,035,191 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 46.78 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TALASAZ AMIRALI | Pegawai | 09 Jun 2025 | Jual automatik (-) | 77,853 | 49.53 | 3,856,059 |
| TALASAZ AMIRALI | Pegawai | 06 Jun 2025 | Jual automatik (-) | 39,751 | 48.06 | 1,910,433 |
| TALASAZ AMIRALI | Pegawai | 05 Jun 2025 | Jual automatik (-) | 1,680 | 48.41 | 81,329 |
| JOYCE MEGHAN V. | Pengarah | 04 Jun 2025 | Pelaksanaan pilihan | 67 | - | - |
| KALIA KUMUD | Pegawai | 03 Jun 2025 | Jual (-) | 4,000 | 45.79 | 183,160 |
| JOYCE MEGHAN V. | Pengarah | 02 Jun 2025 | Jual (-) | 100 | 42.10 | 4,210 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |